Oral candidiasis pathophysiology: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 16: Line 16:


====Candida Virulence factors====
====Candida Virulence factors====
The main virulence factors that mediate the infection:<ref name="pmid23302789">{{cite journal |vauthors=Mayer FL, Wilson D, Hube B |title=Candida albicans pathogenicity mechanisms |journal=Virulence |volume=4 |issue=2 |pages=119–28 |year=2013 |pmid=23302789 |pmc=3654610 |doi=10.4161/viru.22913 |url=}}</ref>
The main [[virulence factors]] that mediate the infection:<ref name="pmid23302789">{{cite journal |vauthors=Mayer FL, Wilson D, Hube B |title=Candida albicans pathogenicity mechanisms |journal=Virulence |volume=4 |issue=2 |pages=119–28 |year=2013 |pmid=23302789 |pmc=3654610 |doi=10.4161/viru.22913 |url=}}</ref>
*Secreting '''molecules that mediate adherence''' into host cells
*Secreting '''molecules that mediate adherence''' into host cells
*Production of '''[[hydrolases]]''' which has a [[Lytic|lytic effect]] on tissues and facilitate the invasion by the fungus.
*Production of '''[[hydrolases]]''' which has a [[Lytic|lytic effect]] on tissues and facilitate the invasion by the [[fungus]].
*'''[[Polymorphism]]:''' [[Candida]] has the ability to grow either as [[Hyphae|pseudohyphae]] (elongated ellipsoid form) or in a [[Yeast|yeast form]] (rounded to oval budding form. While the role of polymorphism is not clearly understood in the [[virulence]] of [[Candida]], it’s noted that the species that are capable of producing the most severe form of the disease has this ability.
*'''[[Polymorphism]]:''' [[Candida]] has the ability to grow either as [[Hyphae|pseudohyphae]] (elongated ellipsoid form) or in a [[Yeast|yeast form]] (rounded to oval budding form. While the role of polymorphism is not clearly understood in the [[virulence]] of [[Candida]], it’s noted that the species that are capable of producing the most severe form of the disease has this ability.
*'''[[Biofilm|Biofilm production]]:''' which means the ability to form a thick layer of the [[organism]] on the [[Mucosal|mucosal surfaces]] or even on [[catheters]] and [[dentures]].
*'''[[Biofilm|Biofilm production]]:''' which means the ability to form a thick layer of the [[organism]] on the [[Mucosal|mucosal surfaces]] or even on [[catheters]] and [[dentures]].
Any condition that compromises [[Cell-mediated immunity|cell mediated immunity]], worsens the general status of the patient or provide a favorable medium for [[Candida]] to form [[biofilms]]  put the patient at increased risk for having candidiasis.<ref name="pmid16984866">{{cite journal |vauthors=Pappas PG |title=Invasive candidiasis |journal=Infect. Dis. Clin. North Am. |volume=20 |issue=3 |pages=485–506 |year=2006 |pmid=16984866 |doi=10.1016/j.idc.2006.07.004 |url=}}</ref>
Any condition that compromises [[Cell-mediated immunity|cell mediated immunity]], worsens the general status of the patient or provide a favorable medium for [[Candida]] to form [[biofilms]]  put the patient at increased risk for having candidiasis.<ref name="pmid16984866">{{cite journal |vauthors=Pappas PG |title=Invasive candidiasis |journal=Infect. Dis. Clin. North Am. |volume=20 |issue=3 |pages=485–506 |year=2006 |pmid=16984866 |doi=10.1016/j.idc.2006.07.004 |url=}}</ref>


Candidal gene VPS4 plays an important role in oropharyngeal candidiasis specifically. Moreover, fungi with mutations affecting this gene was found to be less virulent.<ref name="pmid25483774">{{cite journal |vauthors=Rane HS, Hardison S, Botelho C, Bernardo SM, Wormley F, Lee SA |title=Candida albicans VPS4 contributes differentially to epithelial and mucosal pathogenesis |journal=Virulence |volume=5 |issue=8 |pages=810–8 |year=2014 |pmid=25483774 |doi=10.4161/21505594.2014.956648 |url=}}</ref><ref name="pmid18814053">{{cite journal |vauthors=Lee SA, Jones J, Hardison S, Kot J, Khalique Z, Bernardo SM, Lazzell A, Monteagudo C, Lopez-Ribot J |title=Candida albicans VPS4 is required for secretion of aspartyl proteases and in vivo virulence |journal=Mycopathologia |volume=167 |issue=2 |pages=55–63 |year=2009 |pmid=18814053 |doi=10.1007/s11046-008-9155-7 |url=}}</ref>
[[Gene|Candidal gene]] VPS4 plays an important role in oropharyngeal candidiasis specifically. Moreover, fungi with mutations affecting this [[gene]] was found to be less virulent.<ref name="pmid25483774">{{cite journal |vauthors=Rane HS, Hardison S, Botelho C, Bernardo SM, Wormley F, Lee SA |title=Candida albicans VPS4 contributes differentially to epithelial and mucosal pathogenesis |journal=Virulence |volume=5 |issue=8 |pages=810–8 |year=2014 |pmid=25483774 |doi=10.4161/21505594.2014.956648 |url=}}</ref><ref name="pmid18814053">{{cite journal |vauthors=Lee SA, Jones J, Hardison S, Kot J, Khalique Z, Bernardo SM, Lazzell A, Monteagudo C, Lopez-Ribot J |title=Candida albicans VPS4 is required for secretion of aspartyl proteases and in vivo virulence |journal=Mycopathologia |volume=167 |issue=2 |pages=55–63 |year=2009 |pmid=18814053 |doi=10.1007/s11046-008-9155-7 |url=}}</ref>


===Gross Pathology===
===Gross Pathology===
Line 29: Line 29:


====Pseudomembranous candidiasis:====
====Pseudomembranous candidiasis:====
On speculum examination typical curdy white discharge is present. Usually present in newborns or in patients with deficient immunity, administering corticosteroids, etc.
On speculum examination typical curdy white discharge is present. Usually present in newborns or in patients with [[Immunodeficiency|deficient immunity]], administering [[corticosteroids]], etc.


====Atrophic candidiasis:====
====Atrophic candidiasis:====
Appears as erythema  or edema without the characteristic white plaques. Usually seed in patients with dental dentures.<ref name="pmid7936588">{{cite journal |vauthors=Lynch DP |title=Oral candidiasis. History, classification, and clinical presentation |journal=Oral Surg. Oral Med. Oral Pathol. |volume=78 |issue=2 |pages=189–93 |year=1994 |pmid=7936588 |doi= |url=}}</ref>
Appears as [[erythema]] or [[edema]] without the characteristic [[Plaques|white plaques]]. Usually seed in patients with dental dentures.<ref name="pmid7936588">{{cite journal |vauthors=Lynch DP |title=Oral candidiasis. History, classification, and clinical presentation |journal=Oral Surg. Oral Med. Oral Pathol. |volume=78 |issue=2 |pages=189–93 |year=1994 |pmid=7936588 |doi= |url=}}</ref>


====Chronic hyperplastic candidiasis (Candidal leukoplakia):====
====Chronic hyperplastic candidiasis (Candidal leukoplakia):====
Persistent tough, adherent, white lesions that are indistinguishable from other leukoplakia except through biopsy.
Persistent tough, adherent, white lesions that are indistinguishable from other [[leukoplakia]] except through [[biopsy]].
Seen more in smokers, patients with iron deficiency anemia or deficient cell mediated immunity.<ref name="urlCHRONIC HYPERPLASTTC CANDIDIASIS—CANDIDAL LEUKOPLAKIA - CAWSON - 1968 - British Journal of Dermatology - Wiley Online Library">{{cite web |url=http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2133.1968.tb11899.x/full |title=CHRONIC HYPERPLASTTC CANDIDIASIS—CANDIDAL LEUKOPLAKIA - CAWSON - 1968 - British Journal of Dermatology - Wiley Online Library |format= |work= |accessdate=}}</ref><ref name="pmid7936588">{{cite journal |vauthors=Lynch DP |title=Oral candidiasis. History, classification, and clinical presentation |journal=Oral Surg. Oral Med. Oral Pathol. |volume=78 |issue=2 |pages=189–93 |year=1994 |pmid=7936588 |doi= |url=}}</ref>
Seen more in smokers, patients with [[iron deficiency anemia]] or [[Cell mediated immunity|deficient cell mediated immunity]].<ref name="urlCHRONIC HYPERPLASTTC CANDIDIASIS—CANDIDAL LEUKOPLAKIA - CAWSON - 1968 - British Journal of Dermatology - Wiley Online Library">{{cite web |url=http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2133.1968.tb11899.x/full |title=CHRONIC HYPERPLASTTC CANDIDIASIS—CANDIDAL LEUKOPLAKIA - CAWSON - 1968 - British Journal of Dermatology - Wiley Online Library |format= |work= |accessdate=}}</ref><ref name="pmid7936588">{{cite journal |vauthors=Lynch DP |title=Oral candidiasis. History, classification, and clinical presentation |journal=Oral Surg. Oral Med. Oral Pathol. |volume=78 |issue=2 |pages=189–93 |year=1994 |pmid=7936588 |doi= |url=}}</ref>


====Chronic mucocutaneous  candidiasis (CMCC):====
====Chronic mucocutaneous  candidiasis (CMCC):====
*CMCC is a syndrome characterized by chronic or recurrent superficial candida infection in the skin and mucous membranes in association with endocrinal and autoimmune deficiencies.<ref name="pmid21350122">{{cite journal |vauthors=Puel A, Cypowyj S, Bustamante J, Wright JF, Liu L, Lim HK, Migaud M, Israel L, Chrabieh M, Audry M, Gumbleton M, Toulon A, Bodemer C, El-Baghdadi J, Whitters M, Paradis T, Brooks J, Collins M, Wolfman NM, Al-Muhsen S, Galicchio M, Abel L, Picard C, Casanova JL |title=Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity |journal=Science |volume=332 |issue=6025 |pages=65–8 |year=2011 |pmid=21350122 |pmc=3070042 |doi=10.1126/science.1200439 |url=}}</ref>
*[[Chronic mucocutaneous candidiasis|CMCC]] is a syndrome characterized by chronic or recurrent superficial candida infection in the skin and mucous membranes in association with [[Endocrinopathy|endocrinal]] and [[autoimmune diseases]].<ref name="pmid21350122">{{cite journal |vauthors=Puel A, Cypowyj S, Bustamante J, Wright JF, Liu L, Lim HK, Migaud M, Israel L, Chrabieh M, Audry M, Gumbleton M, Toulon A, Bodemer C, El-Baghdadi J, Whitters M, Paradis T, Brooks J, Collins M, Wolfman NM, Al-Muhsen S, Galicchio M, Abel L, Picard C, Casanova JL |title=Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity |journal=Science |volume=332 |issue=6025 |pages=65–8 |year=2011 |pmid=21350122 |pmc=3070042 |doi=10.1126/science.1200439 |url=}}</ref>
*Characterized by inability of T cells to react to candidal antigens. Presents with: Recurrent or chronic candidal infections. Infection is usually superficial though invasive candidiasis is encountered especially in new born.<ref name="pmid18615114">{{cite journal |vauthors=Eyerich K, Foerster S, Rombold S, Seidl HP, Behrendt H, Hofmann H, Ring J, Traidl-Hoffmann C |title=Patients with chronic mucocutaneous candidiasis exhibit reduced production of Th17-associated cytokines IL-17 and IL-22 |journal=J. Invest. Dermatol. |volume=128 |issue=11 |pages=2640–5 |year=2008 |pmid=18615114 |doi=10.1038/jid.2008.139 |url=}}</ref>
*Characterized by inability of [[T cells]] to react to [[Antigens|candidal antigens]].  
*Enocrinopathies as hypoparathyroidism and adrenal insufficiency may accompany chronic candidiasis.
*Presents with recurrent or chronic candidal infections. Infection is usually superficial though invasive candidiasis is encountered especially in [[Immunosuppression|immunocompromised patients]].<ref name="pmid18615114">{{cite journal |vauthors=Eyerich K, Foerster S, Rombold S, Seidl HP, Behrendt H, Hofmann H, Ring J, Traidl-Hoffmann C |title=Patients with chronic mucocutaneous candidiasis exhibit reduced production of Th17-associated cytokines IL-17 and IL-22 |journal=J. Invest. Dermatol. |volume=128 |issue=11 |pages=2640–5 |year=2008 |pmid=18615114 |doi=10.1038/jid.2008.139 |url=}}</ref>
*[[Endocrinopathy|Endocrinopathies]] as [[hypoparathyroidism]] and [[adrenal insufficiency]] may accompany chronic candidiasis.


<div align="center">
<div align="center">
Line 52: Line 53:


===Microscopic pathology:===
===Microscopic pathology:===
*Microscopic examination of the wet mount with 10% KOH or saline demonstrates hyphae, pseudohyphae and blastospores.
*Microscopic examination of the wet mount with 10% KOH or saline demonstrates [[hyphae]], pseudohyphae and [[Yeast|blastospores]].


==Videos==
==Videos==

Revision as of 01:27, 10 May 2017

Oral candidiasis Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Oral candidiasis from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Oral candidiasis pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Oral candidiasis pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Oral candidiasis pathophysiology

CDC on Oral candidiasis pathophysiology

Oral candidiasis pathophysiology in the news

Blogs on Oral candidiasis pathophysiology

Directions to Hospitals Treating Oral candidiasis

Risk calculators and risk factors for Oral candidiasis pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.

Overview

Candida is a normal commensal of the skin and mucous membranes. The balance between the virulence of the fungus and the host immune defense is responsible avoiding opportunistic infection of candida. Deficiency of cell-mediated immunity or poor general status are the main risk factors for having opportunistic candidiasis. Candidiasis is usually localized to skin and mucous membranes. In rare cases, candidiasis can spread causing candidaemia and distant infection. These cases are usually associated with deficient immunity C. albicans is the main species causing infection in humans more than any other candida species.

Pathophysiology

Pathogenesis

Candida is a normal commensal of skin and mucous membranes. A competent immune system and an intact regenerating healthy skin prevent the virulence of Candida.

Candida Virulence factors

The main virulence factors that mediate the infection:[1]

Any condition that compromises cell mediated immunity, worsens the general status of the patient or provide a favorable medium for Candida to form biofilms put the patient at increased risk for having candidiasis.[2]

Candidal gene VPS4 plays an important role in oropharyngeal candidiasis specifically. Moreover, fungi with mutations affecting this gene was found to be less virulent.[3][4]

Gross Pathology

Oropharyngeal Candidiasis can be in one of 4 forms:[5]

Pseudomembranous candidiasis:

On speculum examination typical curdy white discharge is present. Usually present in newborns or in patients with deficient immunity, administering corticosteroids, etc.

Atrophic candidiasis:

Appears as erythema or edema without the characteristic white plaques. Usually seed in patients with dental dentures.[6]

Chronic hyperplastic candidiasis (Candidal leukoplakia):

Persistent tough, adherent, white lesions that are indistinguishable from other leukoplakia except through biopsy. Seen more in smokers, patients with iron deficiency anemia or deficient cell mediated immunity.[7][6]

Chronic mucocutaneous candidiasis (CMCC):

Microscopic pathology:

  • Microscopic examination of the wet mount with 10% KOH or saline demonstrates hyphae, pseudohyphae and blastospores.

Videos

{{#ev:youtube|Qqb6vZtXxu8}}

References

  1. Mayer FL, Wilson D, Hube B (2013). "Candida albicans pathogenicity mechanisms". Virulence. 4 (2): 119–28. doi:10.4161/viru.22913. PMC 3654610. PMID 23302789.
  2. Pappas PG (2006). "Invasive candidiasis". Infect. Dis. Clin. North Am. 20 (3): 485–506. doi:10.1016/j.idc.2006.07.004. PMID 16984866.
  3. Rane HS, Hardison S, Botelho C, Bernardo SM, Wormley F, Lee SA (2014). "Candida albicans VPS4 contributes differentially to epithelial and mucosal pathogenesis". Virulence. 5 (8): 810–8. doi:10.4161/21505594.2014.956648. PMID 25483774.
  4. Lee SA, Jones J, Hardison S, Kot J, Khalique Z, Bernardo SM, Lazzell A, Monteagudo C, Lopez-Ribot J (2009). "Candida albicans VPS4 is required for secretion of aspartyl proteases and in vivo virulence". Mycopathologia. 167 (2): 55–63. doi:10.1007/s11046-008-9155-7. PMID 18814053.
  5. Epstein JB, Polsky B (1998). "Oropharyngeal candidiasis: a review of its clinical spectrum and current therapies". Clin Ther. 20 (1): 40–57. PMID 9522103.
  6. 6.0 6.1 Lynch DP (1994). "Oral candidiasis. History, classification, and clinical presentation". Oral Surg. Oral Med. Oral Pathol. 78 (2): 189–93. PMID 7936588.
  7. "CHRONIC HYPERPLASTTC CANDIDIASIS—CANDIDAL LEUKOPLAKIA - CAWSON - 1968 - British Journal of Dermatology - Wiley Online Library".
  8. Puel A, Cypowyj S, Bustamante J, Wright JF, Liu L, Lim HK, Migaud M, Israel L, Chrabieh M, Audry M, Gumbleton M, Toulon A, Bodemer C, El-Baghdadi J, Whitters M, Paradis T, Brooks J, Collins M, Wolfman NM, Al-Muhsen S, Galicchio M, Abel L, Picard C, Casanova JL (2011). "Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity". Science. 332 (6025): 65–8. doi:10.1126/science.1200439. PMC 3070042. PMID 21350122.
  9. Eyerich K, Foerster S, Rombold S, Seidl HP, Behrendt H, Hofmann H, Ring J, Traidl-Hoffmann C (2008). "Patients with chronic mucocutaneous candidiasis exhibit reduced production of Th17-associated cytokines IL-17 and IL-22". J. Invest. Dermatol. 128 (11): 2640–5. doi:10.1038/jid.2008.139. PMID 18615114.

Template:WH Template:WS